EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[ESD ÀýÁ¦ Ç¥º»ÀÇ ¸²ÇÁ°ü ħÀ±. Endolymphatic tumor emboli]

Endolymphatic tumor emboli in the upper submucosal layer in mucosal cancer

Multiple endolymphatic tumor emboli in the upper submucosal layer in mucosal cancer. ÀÌ È¯ÀÚÀÇ ¼ö¼ú º´¸®¿¡¼­ lymph node 1°³¿¡ ÀüÀÌ°¡ ÀÖ¾úÀ½


1. ³»½Ã°æÀ¸·Î ÀýÁ¦ÇÑ ºÐÈ­Çü Á¡¸·¾Ï¿¡¼­ ¸²ÇÁ¼± ħÀ±

2016³â 1¿ùÈ£ Gastric Cancer Áö¿¡ Kyoto Prefectural University¿¡¼­ ³»½Ã°æÀ¸·Î ÀýÁ¦ÇÑ ºÐÈ­Çü Á¡¸·¾Ï¿¡¼­ ¸²ÇÁ¼± ħÀ±À» ºÐ¼®ÇÑ °á°ú¸¦ ¹ßÇ¥ÇÏ¿´½À´Ï´Ù (Fujita Y. Gastric Cancer 2016). Pure differentiated type 286¸í Áß 3¸í(1%)¿¡¼­ lymphatic invasionÀÌ ÀÖ¾ú°í, mixed predominantly differentiated type 14¸í Áß 3¸í(21.4%)¿¡¼­ lymphatic invasionÀÌ ÀÖ¾ú½À´Ï´Ù (p = 0.015). Áï ³»½Ã°æÀ¸·Î Ä¡·áÇÑ differentiated mucosal cancer¿¡¼­ lymphatic invasionÀÌ ÀÖ´ø °æ¿ì 6¿¹ Áß 3¿¹¿¡¼­ mixed typeÀ̾ú½À´Ï´Ù. ¿ª½Ã mixed typeÀº ÁÁÁö ¾ÊÀº ³à¼®µéÀÔ´Ï´Ù.


[2016-3-26. ¾Öµ¶ÀÚ ÆíÁö]

±³¼ö´Ô, Àß Áö³»½ÃÁÒ? ÀÌÁ¦ ¼­¿ï¿¡¼­ ºÎ»êÀ¸·Î ¿Å±ä XXXÀÔ´Ï´Ù. ¿À´Ã EndoTODAY Àß º¸¾Ò½À´Ï´Ù.

±³¼ö´Ô ¸»¾¸Ã³·³ Mixed typeÀÌ Ç×»ó ¹®Á¦ ÀÎ °Í °°Àºµ¥, ±³¼ö´Ô²²¼­ À̾߱âÇÏ´Â extended criteria¿Í indicationÀÇ Â÷ÀÌó·³, Mixed typeÀ¸·Î ³ª¿ÔÀ» ¶§ ¾î¶² °É dominant·Î ÇÏ´Â°Ô ¸Â´Â°¡? °ú¿¬ Áö±Ýó·³ %ÇÏ´Â °ÍÀÌ ¸Â´Â°¡? ÀÏ´Ü ÇÑ ¼¼Æ÷°¡ MD³ª PD·Î º¯ÇüµÇ¾úÀ¸¸é °¡Àå ¾È ÁÁÀº °ÍÀ» ±âº»À¸·Î »ý°¢ÇÏ´Â °ÍÀÌ ¸ÂÁö´Â ¾Ê´Â°¡? Àú´Â ÀÌ·± °í¹ÎÀÌ µË´Ï´Ù.

¿¹Àü °Ç±¹´ë À̼±¿µ±³¼ö´Ô ¹ßÇ¥ ÈÄ Åä·Ð¿¡¼­ ÀϺ»¿¡¼­´Â ¿¹Àü¿¡ pathologistÀÇ ±âÁØÀÌ °¡Àå ½ÉÇÑ°Ô Çϳª¶óµµ ÀÖÀ¸¸é ½ÉÇÑ ºÐÈ­µµ·Î Ç¥½ÃÇߴµ¥, ÃÖ±Ù¿¡ ¹Ù²î¾î¼­ ¿ì¸®³ª¶ó ó·³ 80%(MD) 20%(PD) ÀÌ·±½ÄÀ¸·Î Ç¥ÇöÇÏ°Ô µÇ¾ú´Ù°í ÇÕ´Ï´Ù. ÇÏÁö¸¸ ¹Ù²ï °¡À̵å¶óÀÎÀ¸·Î Æǵ¶ÇÏÁö ¾Ê¾Æ¼­ º´¸®ÇÐÀÚ¸¶´Ù ´Ù¸£´Ù°í ÇÕ´Ï´Ù.

Á¦°¡ ÀÌ·± °í¹Î°ú ÇÔ²², ÀÌ·± ¸ÞÀÏÀ» º¸³»°Ô µÈ ÀÌÀ¯´Â ½ÇÀº ±³¼ö´Ô²²¼­ º¸³»½Å Å×À̺íÀÇ ¾àÀÚÀÇ ¿ÀÇØ ¶§¹®ÀÔ´Ï´Ù. ´ÙÇàÈ÷ º»¹®¿¡¼­ Ç®¾î ½áÁֽðí, ³í¹®µµ µé¾î°¡ºÁ¼­ ¾Ë°Ô µÇ¾úÁö¸¸
Pure differentiated type = PD
mixed predominantly differentiated type = MD

Histology typeÀ̶ó´Â Ç׸ñ¿¡ ÀÌ·¸°Ô ¾´ ¾àÀÚ´Â ÈçÈ÷ ¿ì¸®°¡ Ç¥±âÇÏ´Â Poorly differentiated, Moderate differentiated¿Í ¿ÀÇØÀÇ ¼ÒÁö°¡ ÀÖ´Ù°í »ý°¢µË´Ï´Ù. ^^

Àú¿¡°Ô EndoTODAY´Â ¸ÅÀÏ °øºÎÇÒ ¼ö ÀÖ´Â ¿øµ¿·Â°ú ÁÖÁ¦°¡ µË´Ï´Ù. ²É»ù ÃßÀ§ °¡¿îµ¥ °¨±â Á¶½ÉÇϽñ⠹ٶø´Ï´Ù.

[2016-3-26. ÀÌÁØÇà ´äº¯]

±ä fellow »ýÈ°À» ¸¶Ä¡°í µåµð¾î ¹ß·É¹ÞÀ¸½Å °ÍÀ» ÃàÇÏÇÕ´Ï´Ù. ¾Æ·¡ tableÀÇ PD, MD¶ó´Â ¾àÀÚ°¡ È¥¶õ·´´Ù´Â ÁöÀû °¨»çÇÕ´Ï´Ù.

»ç½Ç ÀϺ»ÀεéÀº ¿ë¾î¸¦ ´ëÃæ »ç¿ëÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ¿ì¸®´Â À¯±³ ¹®È­±ÇÀ̹ǷΠ¸»(= ¿ë¾îÀÇ Á¤ÀÇ) °¡Áö°í ½Î¿ì´Â ÀüÅëÀÌ ÀÖ½À´Ï´Ù. ÀϺ»Àº ÈξÀ practical ÇÕ´Ï´Ù. ´Ù¼Ò ÀÌ»óÇÏ´õ¶óµµ À¯¿ëÇÏ¸é °è¼Ó ¾²´Â °ÍÀÌ ±×µé ¹æ½ÄÀÔ´Ï´Ù. ¿¹¸¦ µé¸é early gastric cancer°¡ ¾îµð early Çմϱî? ±íÁö ¾ÊÀ» »ÓÀÌÁö¿ä. 'ÀÏÂï'À̶ó´Â ¶æÀÇ 'early'¿Í´Â º° »ó°ü ¾ø´Â Áø´Ü¸íÀÔ´Ï´Ù. ±×³É °ú°ÅºÎÅÍ ½á¿Ô°í ³ª¸§ À¯¿ëÇϱ⠶§¹®¿¡ ³öµÑ »ÓÀÔ´Ï´Ù. ¿ì¸® °°¾ÒÀ¸¸é ¹ú½á ¹Ù²åÀ» °ÍÀÔ´Ï´Ù. ÀϺ»Àº À̸§À» Àß ¹Ù²ÙÁö ¾Ê½À´Ï´Ù. ¿ì¸®´Â À̸§À» ÀÚÁÖ ¹Ù²ß´Ï´Ù. ±× Áß°£ÀÌ µü ÁÁ°Ú´Âµ¥... ('ÇàÁ¤¾ÈÀüºÎ'¸¦ '¾ÈÀüÇàÁ¤ºÎ'·Î ¹Ù²Ù´Â ±×·± ÀÏÀº ÀϺ»¿¡¼­´Â º¸±â ¾î·Á¿ï °Í °°½À´Ï´Ù.)

¿ì¸®ÀÇ ¹®Á¦´Â ÀϺ»°ú ¹Ì±¹ »çÀÌ¿¡¼­ 70³â° Çì¸Å°í ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. ¸¹Àº ¼±»ý´ÔµéÀº ¹Ì±¹À» ÃßÁ¾ÇÏ¿© ¹Ì±¹ ³í¹®À» Àаí, ¹Ì±¹ ÇÐȸ¿¡ °¡°í, ¹Ì±¹À¸·Î ¿¬¼ö¸¦ °©´Ï´Ù. ³í¹®µµ ¹Ì±¹½ÄÀ¸·Î ¾²°í, ¹Ì±¹ Àú³Î¿¡ ¹ßÇ¥ÇÕ´Ï´Ù. ¾î¶² ¼±»ý´ÔµéÀº ÀϺ»½ÄÀ¸·Î ÀÏÇÏ´Â °Í °°Àºµ¥, ½º½º·Î´Â ¹Ì±¹½ÄÀ̶ó°í ÁÖÀåÇÕ´Ï´Ù. È¥¶õ½º·´½À´Ï´Ù.

¹Ì±¹¿¡¼­´Â ¹Ì±¹½Ä ÀÇÇÐÀÌ Ç¥ÁØÀ̹ǷΠȥ¶õÀÌ ¾ø½À´Ï´Ù. ÀϺ»¿¡¼­µµ ¸¶Âù°¡ÁöÀÔ´Ï´Ù. ÀϺ»¿¡¼­´Â ÀϺ»½Ä ÀÇÇÐÀÌ Ç¥ÁØÀ̹ǷΠȥ¶õÀÌ ¾ø½À´Ï´Ù. ¹Ì±¹ÀεéÀÌ ÀÌ»óÇÏ´Ù°í ¸»Çصµ ÀϺ»ÀεéÀº ²ô¶±µµ ¾Ê½À´Ï´Ù. ¹Ì±¹°ú ÀϺ»Àº ´Ù¸£´Ù°í »ý°¢ÇÒ »ÓÀÔ´Ï´Ù. ¿ì¸®´Â µÑ »çÀÌ¿¡¼­ ¿Ô´Ù °¬´Ù ÇÕ´Ï´Ù. Á¶±Ý °úÀåÇÏ¸é ¿ì¸®¸¸ È¥¶õ½º·´½À´Ï´Ù.

´äÀº ÇϳªÀÔ´Ï´Ù. '¿ì¸®ÀÇ ÀÇÇÐ'À» Á¤¸³ÇÏ´Â °ÍÀÔ´Ï´Ù. ¹Ì±¹µµ ÀϺ»µµ Á¤´äÀÌ ¾Æ´Õ´Ï´Ù. ¿ì¸® ȯ°æ¿¡ ¸Â´Â '¿ì¸®ÀÇ ÀÇÇÐ'À» Ãß±¸ÇØ¾ß ¹®Á¦°¡ Ç®¸³´Ï´Ù. ±¤º¹ 70³âÀÔ´Ï´Ù. ÀÌÁ¦´Â ÀÇÇеµ µ¶¸³ÇØ¾ß ÇÕ´Ï´Ù.

ÁöÀûÇϽŠÀϺ» ³í¹®ÀÇ ¾Ö¸ÅÇÑ ¾àÀÚ¿¡ ´ëÇؼ­´Â Ç¥ ¾Æ·¡¿¡ º¸Ãæ ¼³¸íÀ» ºÙ¿´½À´Ï´Ù. ÁÁÀº ÀÇ°ß °¨»çÇÕ´Ï´Ù.


2. 1±â À§¾Ï Àç¹ßÀ§ÇèÀÎÀÚ

2016³â 1¿ùÈ£ Gastric CancerÁö¿¡ ¾Æ»êº´¿ø ¿Ü°ú¿¡¼­ 1±â À§¾Ï Àç¹ßÀ§ÇèÀÎÀÚ¸¦ ºÐ¼®ÇÑ °á°ú¸¦ º¸°íÇÏ¿´½À´Ï´Ù (Park JH. Gastric Cancer 2016). 6°³ÀÇ independent risk factor°¡ Á¦½ÃµÇ¾ú½À´Ï´Ù. ¸²ÇÁÀý ÀüÀ̺¸´Ù´Â lymphovascular invasionÀÌ ´õ Áß¿äÇÏ´Ù´Â ¸»Àϱî¿ä?


3. Lymphovascular invasion in forceps biopsy

Shallow ulcerative EGC was found in the 70 YO female. ESD was initially considered. In the repeated biopsy, however, there was lymphovascular invasion (pathology report: Tubular adenocarcinoma, M/D with lymphovascular invasion).

Would you recommend surgery or ESD?

.

.

.

.

.

.

.

I recommended surgery and the final pathology showed lymphatic invasion.

Stomach, radical subtotal gastrectomy: Early gastric carcinoma
1. Location : lower third, Center at antrum and anterior wall
2. Gross type : EGC type IIb
3. Histologic type : tubular adenocarcinoma, moderately differentiated
4. Histologic type by Lauren : mixed
5. Size : 1.5x1.0 cm
6. Depth of invasion : invades mucosa (muscularis mucosae) (pT1a)
7. Resection margin: free from carcinoma, safety margin: proximal 6.5 cm, distal 4.0 cm
8. Lymph node metastasis : no metastasis in 30 regional lymph nodes (pN0)
9. Lymphatic invasion : present
10. Venous invasion : not identified
11. Perineural invasion : not identified
12. AJCC stage by 8th edition: pT1a N0

¿ÜºÎ ³»½Ã°æ »çÁøÀÌ ÁÁ¾Ò´Ù¸é ³»½Ã°æ Àç°Ë ¾øÀÌ ³»½Ã°æ Ä¡·á¸¦ ÇßÀ» °ÍÀÔ´Ï´Ù. Àú¿¡°Ô ÀÇ·ÚµÈ È¯ÀÚÀÇ 80% Á¤µµ´Â ³»½Ã°æ Àç°Ë ¾øÀÌ ESD¸¦ ÇÏ°í ÀÖ½À´Ï´Ù. ¿ÜºÎ »çÁø¿¡¼­ ÃÖ¼ÒÇÑÀÇ Á¤º¸¸¦ ¾ò±â ¾î·Á¿î 20%¿¡¼­¸¸ Àç°ËÀ» ÇÕ´Ï´Ù.

ÀÌ È¯ÀÚ¿¡¼­´Â ³»½Ã°æ Àç°Ë Á¶Á÷°Ë»ç¿¡¼­ lymphovascular invasionÀÌ ÀÖ¾úÀ¸¹Ç·Î ¼ö¼úÀ» ±ÇÀ¯ÇßÁö, ¸¸¾à ¹Ù·Î ESD¸¦ ½ÃÇàÇÏ¿© ÀÌ·± °á°ú°¡ ³ª¿Ô´Ù¸é »ó´çÈ÷ °í¹ÎÇßÀ» °Í °°½À´Ï´Ù. ÃÖ±Ù¿¡´Â ¾Æ·¡ ÀÚ·á¿¡ ±Ù°ÅÇÏ¿© Á¡¸·¾ÏÀÌ 2cm º¸´Ù ÀÛ°í ´Ù¸¥ À§ÇèÀÎÀÚ°¡ ¾øÀÌ lymphatic invasion¸¸ ÀÖ´Ù¸é, º´¸®°ú ¼±»ý´Ô°ú ESD specimenÀ» ¸®ºäÇÏ¿© lymphatic invasionÀÌ ½ÉÇÏÁö ¾ÊÀ¸¸é °æ°ú°üÂûÀ» ¼±ÅÃÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.

Maybe we are doing too much surgery after ESD. Do you think surgery is necessary for mucosal cancer with lymphovascular invasion? As you can see in the red box, in lymphovascular invasion positive patients within the traditional absolute indication ? mucosal cancer, differentiated type, no ulcer, less than 2 cm, there was no lymph node metastasis in surgery. Careful observation without additional surgery can be an option for this group of patients.

À§¾Ï ESD´Â ¸Å¿ì ¼¶¼¼ÇÑ Ä¡·áÀ̸ç, »ç¼ÒÇÑ ¼Ò°ß¿¡ ÀÇÇÏ¿© Å« Â÷ÀÌ°¡ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. À§¾Ï °ËÁø ³»½Ã°æÀ» ´ã´çÇÏ´Â ¼±»ý´ÔµéÀÌ ÀÌ Á¡À» °¢º°È÷ ÁÖÀÇÇØ¾ß ÇÒ °ÍÀÔ´Ï´Ù. (1) ÃæºÐÇÑ °Ë»ç ½Ã°£ (ÃÖ¼ÒÇÑ 5ºÐ), (2) ÀÚ¼¼ÇÑ description, (4) ¿ø°æ°ú ±Ù°æÀÌ ¸ðµÎ ¼±¸íÇÏ°í º´¼ÒÀÇ À§Ä¡, Å©±â, ¸ð¾çÀÌ ¼±¸íÇÑ »çÁø, (4) Á¤È®ÇÑ Á¶Á÷°Ë»ç... ÀÌ ¸ðµç °ÍÀÌ ÇÊ¿äÇÕ´Ï´Ù.

* Âü°í: EndoTODAY À§¾Ï 834


[FAQ]

[2017-12-13]

8³â Àü À§¾Ï ESD ÈÄ ¸í¹éÇÑ lymphatic invasionÀÌ ÀÖ¾î ¼ö¼úÀ» ¹ÞÀ¸¼Ì´ø ºÐÀÌ ¿Ü·¡¿¡¼­ ½Å¹® ±â»ç¸¦ º¸¿©Áָ鼭 "¼ö¼úÇϱæ ÀßÇß´Ù"°í ¸»¾¸Çϼ̽À´Ï´Ù.

¿øÄ¢´ë·Î ÇÏ´Â °ÍÀÌ °¡Àå ¼ÓÆíÇÑ ÀÏÀÔ´Ï´Ù. Àǻ糪 ȯÀÚ³ª...


[References]

1) EndoTODAY À§¾Ï 834



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.